Broadcasting from ACC 2024 - Ankeet Bhatt, MD, MBA: Sacubitril/Valsartan vs ACEi/ARB in de novo HFmrEF/HFpEF

A comparative effectiveness analysis of data from the Optum Electronic Health Record dataset provides insight into the benefit of sacubitril/valsartan (Entresto) relative to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in patients with newly diagnosed heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).

“What we know from the way the FDA has labeled this in recent guidelines is that this therapy is efficacious over ACE or ARB, particularly in patients who have an [ejection fraction] ‘below normal’. Where I think we have had a reasonable data gap is on patients who are newly diagnosed with heart failure,” explained study investigator Ankeet Bhatt, MD, MBA,a research scientist at Kaiser Permanente Northern California and associate physician at Kaiser San Francisco Medical Center. “So, I think this provides us some reassurance that the benefits observed in most of the clinical trial populations can actually extend potentially to patients with de novo heart failure with mildly reduced and or preserved ejection fraction”

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.